Cusi K, et al. - In this double-blind, parallel-group, placebo-controlled, 24-week trial involving 56 patients, researchers assessed the effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on intrahepatic triglyceride (IHTG) accumulation and its relationship to changes in body weight and glucose metabolism. Investigators found that canagliflozin reduced HbA1c and body weight. In patients with T2DM, canagliflozin improves hepatic insulin sensitivity and insulin secretion and clearance. IHTG decreases in proportion to the magnitude of body weight loss that tended to be higher with canagliflozin.